New Study at the ACC Scientific Session Reveals Bariatric Surgery May Be An Option for Obese Diabetics

Monday, 26 March 2012 00:00

CHICAGO, March 26, 2012

A new study released Monday at the American College of Cardiology Scientific Session indicates that bariatric surgery improves glycemic control better than optimal medical therapy alone for obese patients with type 2 diabetes.

In the STAMPEDE (Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently) trial, hemoglobin A1c levels normalized to under 6% in the first year for 42% of gastric bypass surgery patients and 37% of sleeve gastrectomy patients.

Gastric Bypass surgery patients reached the primary endpoint of a glycosylated hemoglobin under 6.0% without the use of diabetes medications and all patients reduced cardiovascular risk factors including hypertension and weight.

Jane Nelson-Worel, MSN, APRN-BC, APNP, FAHA, FPCNA, Adult Nurse Practitioner, Meriter Heart & Vascular Hospital, Madison, Wisconsin and member of the Preventive Cardiovascular Nurses Association (PCNA) board of directors, believes that although lifestyle change alone is a preferred method for diabetes and weight control, this is an important trial that could present a new option for patients with an urgent need for risk reduction.

“Diabetes and weight control are important issue in the prevention of cardiovascular disease. Anytime someone can improve diabetic control through lifestyle change alone, that would be preferred. However, we acknowledge that diabetes and obesity is sometimes such a life-threatening problem that this could be a choice for some patients,” says Nelson-Worel. “There will be a group of patients that won’t be able to control diabetes and weight on their own. This is a helpful option and it will benefit them in terms of cardiovascular risk reduction. However, as the study included, it will also be important to implement intensive medical therapy with these types of patients, including lifestyle counseling and weight management.”

More details about the STAMPEDE trial can be found on Medpage Today.


Medical Expert: Jane Nelson-Worel, MSN, APRN-BC, APNP, FAHA, FPCNA: Jane Nelson-Worel MSN, APRN-BC, APNP, FAHA, FPCNA coordinates the Cardiovascular Disease in Women Program at the Meriter Heart & Vascular Hospital, in Madison, Wisconsin. She currently serves as the Meriter site coordinator for the VIRGO trial, an NIH funded trial established to better understand the variations in recovery and outcomes after AMI in young men and women. Nelson-Worel is an Adult Nurse Practitioner with over ten years of experience in Preventive Cardiology. Areas of clinical interest include women and heart disease and the management of patients with complex dyslipidemia, hypertension and metabolic syndrome. She has spent most of her career involved in cardiac rehabilitation and health promotion programs in administrative and program development roles. She is a 3-time graduate from the University of Wisconsin, Madison with both MS and BS degrees in Nursing and an MS in Clinical Exercise Physiology. She serves as clinical faculty member for the University of Wisconsin, Madison, School of Nursing – nurse practitioner program.

About PCNA: The Preventive Cardiovascular Nurses Association (PCNA) is the leading nursing organization dedicated to preventing cardiovascular disease (CVD) through assessing risk, facilitating lifestyle changes, and guiding individuals to achieve treatment goals. The mission of PCNA is to promote nurses as leaders in the prevention and management of cardiovascular disease. PCNA does this by educating and supporting nurses through the development of professional and patient education, leadership, and advocacy.

Media Contact: Abby Gutowski, Public Relations and Marketing Manager,, 920.606.2115

Related Articles